Is dermatologic follow-up in metastatic melanoma patients treated with immuno- or targeted therapy necessary?
Malignant melanoma accounts for the highest number of deaths from skin cancer and the incidence is still increasing. Previously, the prognosis has been poor for patients with metastatic disease, with a 3-year overall survival of only 12% when treated with chemotherapy. (1) However, as a result of treatment with targeted therapy (TT) and immunotherapy (IT), the 3-year overall survival increases to 26-58%. (2) Current guidelines recommend dermatologic surveillance in patients with good response, nonetheless good response is not clearly specified and timing and frequency are not stated. (3-5) This study aimed to specify the need for routine skin examination in patients with durable response to TT and IT.